Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 27.1%

Atyr PHARMA INC (NASDAQ:ATYR) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,110,000 shares, an increase of 27.1% from the October 31st total of 1,660,000 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average daily trading volume, of 858,600 shares, the days-to-cover ratio is currently 2.5 days.

Atyr PHARMA Trading Down 0.3 %

Shares of ATYR stock traded down $0.01 during trading hours on Monday, hitting $3.52. 383,298 shares of the company were exchanged, compared to its average volume of 582,763. The company’s fifty day moving average price is $2.75. Atyr PHARMA has a 52-week low of $1.14 and a 52-week high of $3.80. The firm has a market cap of $295.48 million, a PE ratio of -3.76 and a beta of 1.10. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sell-side analysts anticipate that Atyr PHARMA will post -0.89 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ATYR. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, October 29th. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price objective on shares of Atyr PHARMA in a research note on Wednesday, August 14th. Jefferies Financial Group assumed coverage on shares of Atyr PHARMA in a report on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Wells Fargo & Company began coverage on shares of Atyr PHARMA in a report on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price for the company.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.